Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-334543, EGFR/ErbB2 inhibitor · 5 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| ARRY-334543 + gemcitabine | EXPERIMENTAL | - |
| ARRY-334543 + docetaxel + prophylactic growth factors | EXPERIMENTAL | - |
| ARRY-334543 + capecitabine | EXPERIMENTAL | - |
| ARRY-334543 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-334543, EGFR/ErbB2 inhibitor; oral | DRUG | multiple dose, escalating |
| Gemcitabine, nucleoside analogue; intravenous | DRUG | multiple dose, single schedule |
| Docetaxel, mitotic inhibitor; intravenous | DRUG | multiple dose, single schedule |
| Prophylactic growth factors; subcutaneous | DRUG | standard of care |
| Capecitabine, 5-fluorouracil prodrug; oral | DRUG | multiple dose, single schedule |
Key Inclusion Criteria (Part 1): * Histologically or cytologically confirmed diagnosis of a solid tumor suitable for treatment with gemcitabine. * No more than 3 prior anticancer regimens for advanced disease. * Measurable or evaluable, nonmeasurable disease. * Eastern Cooperative Oncology Group (E...
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ARRY-334543 is an investigational oral small molecule being studied in advanced cancer. Clinical trials have evaluated it in patients with advanced solid tumors, including a Phase 1 study in advanced cancer and pancreatic cancer. It has been tested both as a single agent and in combination with chemotherapy agents such as gemcitabine, docetaxel, and capecitabine.
ARRY-334543 targets EGFR and ErbB2, also known as HER2. It is an EGFR/ErbB2 inhibitor, meaning it is designed to block signaling through these two receptor tyrosine kinases. Both targets are commonly implicated in the growth and survival of solid tumors, which is the rationale for studying the drug in advanced cancer.
Pfizer, Inc. is the developer of ARRY-334543. Pfizer trades on the New York Stock Exchange under the ticker PFE. The compound is an oral small molecule EGFR/ErbB2 inhibitor that Pfizer has advanced through early-stage clinical testing in oncology.
ARRY-334543 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. All five of its recorded trials are Phase 1 studies, and all five are completed, with no active trials currently listed. The program enrolled 203 patients in total across those studies.
Five completed Phase 1 trials have evaluated ARRY-334543. These include NCT00862524 with gemcitabine in advanced cancer and pancreatic cancer, NCT00833326 with docetaxel in advanced cancer, NCT00710736 with capecitabine in advanced cancer, and NCT00637702 as a single agent in advanced cancer. The studies were conducted in the United States and Canada.
Yes. ARRY-334543 is also referred to as ARRY-334543, EGFR/ErbB2 inhibitor, oral. These names describe the same investigational compound, an orally administered small molecule that inhibits EGFR and ErbB2. Searches using either name refer to the same Pfizer Phase 1 oncology asset.